| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/27/2023 | 220.51% | HC Wainwright & Co. | → $3.75 | Reiterates | Buy → Buy |
| 08/28/2023 | 220.51% | HC Wainwright & Co. | $2 → $3.75 | Upgrades | Neutral → Buy |
| 08/11/2023 | 70.94% | HC Wainwright & Co. | → $2 | Reiterates | Neutral → Neutral |
| 06/21/2023 | 70.94% | HC Wainwright & Co. | → $2 | Reiterates | Neutral → Neutral |
| 06/14/2023 | 70.94% | HC Wainwright & Co. | → $2 | Reiterates | Neutral → Neutral |
| 06/02/2023 | 70.94% | HC Wainwright & Co. | → $2 | Reiterates | Neutral → Neutral |
| 05/31/2023 | 241.88% | Piper Sandler | $2 → $4 | Upgrades | Neutral → Overweight |
| 05/30/2023 | 70.94% | HC Wainwright & Co. | → $2 | Reiterates | Neutral → Neutral |
| 05/26/2023 | 70.94% | HC Wainwright & Co. | → $2 | Reiterates | Neutral → Neutral |
| 05/09/2023 | 70.94% | Needham | → $2 | Reiterates | → Neutral |
| 04/26/2023 | 70.94% | HC Wainwright & Co. | $1.25 → $2 | Maintains | Neutral |
| 03/31/2023 | 6.84% | HC Wainwright & Co. | → $1.25 | Reiterates | → Neutral |
| 03/10/2023 | 6.84% | HC Wainwright & Co. | → $1.25 | Reiterates | → Neutral |
| 02/22/2023 | 6.84% | HC Wainwright & Co. | → $1.25 | Maintains | Neutral |
| 05/16/2022 | 6.84% | HC Wainwright & Co. | $2 → $1.25 | Maintains | Neutral |
| 03/31/2022 | 70.94% | HC Wainwright & Co. | $10 → $2 | Downgrades | Buy → Neutral |
| 03/31/2022 | — | Needham | Downgrades | Buy → Hold | |
| 03/31/2022 | 70.94% | Mizuho | $6 → $2 | Downgrades | Buy → Neutral |
| 03/31/2022 | 70.94% | Piper Sandler | $8 → $2 | Downgrades | Overweight → Neutral |
| 11/11/2021 | 754.7% | HC Wainwright & Co. | $6 → $10 | Maintains | Buy |
| 03/08/2021 | 583.76% | Cantor Fitzgerald | → $8 | Initiates Coverage On | → Overweight |
| 03/08/2021 | 412.82% | HC Wainwright & Co. | $9 → $6 | Maintains | Buy |
| 01/29/2021 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 10/26/2020 | 669.23% | HC Wainwright & Co. | $10 → $9 | Maintains | Buy |
| 09/04/2020 | 156.41% | Morgan Stanley | $12 → $3 | Maintains | Equal-Weight |
| 09/04/2020 | 412.82% | BTIG | $26 → $6 | Maintains | Buy |
| 09/04/2020 | 754.7% | HC Wainwright & Co. | $17 → $10 | Maintains | Buy |
| 07/15/2020 | 925.64% | Morgan Stanley | $11 → $12 | Maintains | Equal-Weight |
| 05/06/2020 | 1438.46% | JP Morgan | $13 → $18 | Maintains | Overweight |
| 05/06/2020 | 840.17% | Morgan Stanley | $9 → $11 | Maintains | Equal-Weight |
| 05/06/2020 | 1352.99% | HC Wainwright & Co. | $16 → $17 | Maintains | Buy |
| 05/06/2020 | 1352.99% | Mizuho | $15 → $17 | Maintains | Buy |
| 05/05/2020 | 1438.46% | Needham | $15 → $18 | Maintains | Buy |
| 03/11/2020 | 1182.05% | Mizuho | $16 → $15 | Reiterates | → Buy |
| 02/20/2020 | 1011.11% | JP Morgan | $10 → $13 | Maintains | Overweight |
| 11/18/2019 | 1267.52% | HC Wainwright & Co. | $17 → $16 | Maintains | Buy |
| 08/06/2019 | 1352.99% | HC Wainwright & Co. | $19 → $17 | Maintains | Buy |
| 05/02/2019 | — | JP Morgan | Initiates Coverage On | → Overweight | |
| 03/20/2019 | 669.23% | Citigroup | → $9 | Initiates Coverage On | → Neutral |
What is the target price for Akebia Therapeutics (AKBA)?
The latest price target for Akebia Therapeutics (NASDAQ: AKBA) was reported by HC Wainwright & Co. on September 27, 2023. The analyst firm set a price target for $3.75 expecting AKBA to rise to within 12 months (a possible 220.51% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Akebia Therapeutics (AKBA)?
The latest analyst rating for Akebia Therapeutics (NASDAQ: AKBA) was provided by HC Wainwright & Co., and Akebia Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Akebia Therapeutics (AKBA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akebia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akebia Therapeutics was filed on September 27, 2023 so you should expect the next rating to be made available sometime around September 27, 2024.
Is the Analyst Rating Akebia Therapeutics (AKBA) correct?
While ratings are subjective and will change, the latest Akebia Therapeutics (AKBA) rating was a reiterated with a price target of $0.00 to $3.75. The current price Akebia Therapeutics (AKBA) is trading at is $1.17, which is within the analyst's predicted range.